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Abstract
Background: The estimation of the burden of disease attributable to fatty liver requires studies performed in the
general population.
Methods: The Bagnacavallo Study was performed between October 2005 and March 2009. All the citizens of
Bagnacavallo (Ravenna, Italy) aged 30 to 60 years as of January 2005 were eligible. Altered liver enzymes were
defined as alanine transaminase > 40 U/l and/or aspartate transaminase > 37 U/l.
Results: Four thousand and thirty-three (58%) out of 6920 eligible citizens agreed to participate and 3933 (98%)
had complete data. 393 (10%) of the latter had altered liver enzymes and 3540 had not. After exclusion of subjects
with HBV or HCV infection, liver ultrasonography was available for 93% of subjects with altered liber enzymes and
52% of those with normal liver enzymes. The prevalence of fatty liver, non-alcoholic fatty liver disease (NAFLD) and
alcoholic fatty liver disease (AFLD) was 0.74 (95%CI 0.70 to 0.79) vs. 0.35 (0.33 to 0.37), 0.46 (0.41 to 0.51) vs. 0.22
(0.21 to 0.24) and 0.28 (0.24 to 0.33) vs. 0.13 (0.11 to 0.14) in citizens with than in those without altered liver
enzymes. Ethanol intake was not associated and all the components of the metabolic syndrome (MS) were associated
with fatty liver. All potential risk factors were associated with a lower odds of normal liver vs. NAFLD while they were
unable to discriminate AFLD from NAFLD.
Conclusions: Fatty liver as a whole was highly prevalent in Bagnacavallo in 2005/9 and was more common among
citizens with altered liver enzymes.
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Background
Fatty liver (FL), the most common liver disease world-
wide, is usually classified into non-alcoholic fatty liver
disease (NAFLD) and alcoholic fatty liver disease
(AFLD) [1, 2]. After the exclusion of hepatitis B and C
and steatogenic drugs, NAFLD is currently diagnosed
when FL is associated with an ethanol intake ≤20 g/day
in women and ≤ 30 g/day in men [1, 2]. The NAFLD vs.
AFLD dichotomization is useful in clinical practice be-
cause ethanol is unlikely to be toxic at quantities ≤30 g/
day but hides the important fact that ethanol and obesity
do interact to determine the burden of liver disease in
the general population [2–4]. FL is commonly consid-
ered the hepatic manifestation of the metabolic syn-
drome (MS) but the formal testing of the hypothesis
that FL is the hepatic component of MS has led to con-
flicting results [2, 5–7].
In the early 2000s, the Dionysos Study reported the
first data on the prevalence and incidence of FL in the
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general population [8, 9]. In the Dionysos Nutrition &
Liver Study, the citizens of Campogalliano (Modena,
Emilia-Romagna, Italy) with suspected liver disease were
matched with randomly chosen citizens without sus-
pected liver disease to obtain estimates of the prevalence
of and the risk factors for NAFLD and AFLD in the gen-
eral population [8]. Many epidemiological studies on FL
have been published since the Dionysos Nutrition &
Liver Study findings were made available [10]. The
worldwide prevalence of NAFLD was estimated to be
0.25 (95%CI 0.22 to 0.28) by a recent meta-analysis of 45
studies [10]. Eleven of these 45 studies were performed
in Europe and yielded an estimate of 0.24 (0.16 to 0.33)
for the prevalence of NAFLD. Five of these 11 studies
used imaging techniques to diagnose FL and were per-
formed in the general population [3, 8, 11–13], with one
of them being a nested case-control study [3].
The so-called “ecology of medical care” model pro-
vides a strong rationale to expect that the estimates of
illness made in the general population will differ from
those obtained in other settings and this has indeed been
repeatedly shown in practice [14, 15]. The inescapable
conclusion is that the real burden attributable to a given
disease cannot be estimated without epidemiological
data obtained from the general population [15]. There is
also mounting evidence that within a given level of the
ecology of medical care [14], the individuals actually
studied are often not representative of the persons mak-
ing up that level, e.g. the patients enrolled in trials of
NAFLD drugs are not representative of those treated in
everyday practice [16].
It was with the aim of providing data on the epidemi-
ology of FL in the general population that we performed
the Bagnacavallo Study of liver disease. In detail, the aim
of the Bagnacavallo Study was threefold: 1) to evaluate
the prevalence of and the risk factors for FL in a
cross-section of the general population of a Northern
Italy town; 2) to develop a cohort of subjects from the
general population where the association between FL
and incident health outcomes could be studied; 3) to de-
velop a cohort of subjects from the general population
where nested case-control studies of potential risk fac-
tors for FL could be performed (taking the advantage of
a purposely built serum bank) [17].
The present report deals with the first aim of the Bag-
nacavallo Study, i.e. the estimation of the prevalence of
and the risk factors for FL in a general population. We
also report the prevalence of and the risk factors for FL
dichotomized into NAFLD and AFLD.
Methods
Study design
The Bagnacavallo Study was performed between Octo-
ber 2005 and March 2009. All citizens of Bagnacavallo
(Ravenna, Emilia-Romagna, Italy) aged 30 to 60 years as
of January 2005 were eligible and were invited by written
letter to participate to the study. Public encounters were
also held to promote participation to the study. Altered
liver enzymes (ALE) were defined as alanine transaminase
(ALT) > 40 U/l and/or aspartate transaminase (AST) > 37
U/l. These cut-points were the upper normal limits of
ALT and AST applied by the laboratory that performed all
the analyses of the Bagnacavallo study. The study protocol
specified that all ALE+ and at least 50% of ALE- citizens
had to undergo liver ultrasonography (LUS). ALE- citizens
were chosen consecutively on the basis of their surname
starting from a randomly chosen letter of the alphabet.
The study was approved by the Ethical Committee of Area
Vasta Romagna - IRST (reference number 112). All citi-
zens gave written informed consent.
Clinical and anthropometric assessment
All participants underwent a detailed clinical history and
physical examination following the model of the Diony-
sos Study [8, 18]. Current alcohol intake was assessed by
trained interviewers by measuring the quantity (grams)
of beer, wine and liquor drunk in the week prior to the
enrollment [19]. Such quantity was divided by 7 to ob-
tain a daily estimate and converted into alcohol units
with rounding to the next integer. The conversion was
done using an alcohol unit corresponding to 10 g of
ethanol. Weight and height were measured following
international guidelines [20]. Body mass index (BMI)
was calculated and classified following the NIH guide-
lines [21]. Waist circumference (WC) was measured at
the midpoint between the last rib and the iliac crest [22].
Laboratory assessment
Venous blood samples were obtained after 12-h fasting.
The performed blood tests included: 1) glucose; 2) triglycer-
ides; 3) total cholesterol; 4) high-density lipoprotein (HDL)
cholesterol; 5) low-density lipoprotein (LDL) cholesterol; 6)
ALT; 7) AST; 8) gamma-glutamyl-transferase (GGT); 9)
bilirubin; 10) hepatitis B surface antigen (HBsAg); 11) anti-
bodies against hepatitis C virus (anti-HCV).
Metabolic syndrome
The MS was diagnosed using the harmonized international
definition [23]. In detail, large WC was defined as WC ≥
102 cm in men and ≥ 88 cm in women; high triglycerides
as triglycerides ≥150mg/dl or use of triglyceride-lowering
drugs; low HDL as HDL < 40mg/dl in men and < 50mg/dl
in women or use of HDL-increasing drugs; high blood
pressure as systolic blood pressure ≥ 130mmHg or dia-
stolic blood pressure ≥ 85mmHg or use or blood
pressure-lowering drugs; high glucose as glucose ≥100mg/
dl or use of glucose lowering drugs; and MS as ≥3 of the
above.
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Liver ultrasonography
LUS was performed by five experienced physicians
(ACDA, GS, FD, AL and FC) using the same method-
ology of the Dionysos Nutrition & Liver Study [9, 24].
Normal liver was defined as the absence of liver steatosis
or other liver abnormalities. Light FL was defined as the
presence of slight “bright liver” or hepatorenal echo con-
trast without intrahepatic vessels blurring and no deep
attenuation; moderate FL as the presence of mild “bright
liver” or hepatorenal echo contrast without intrahepatic
vessel blurring and with deep attenuation; and severe FL
as diffusely severe “bright liver” or hepatorenal echo
contrast, with intrahepatic vessels blurring (no visible
borders) and deep attenuation without visibility of the
diaphragm. NAFLD was defined as FL associated with
ethanol intake ≤2 alcohol units (20 g) / day in women
and ≤ 3 alcohol units (30 g) / day in men testing negative
for HBsAg and anti-HCV and not treated with steato-
genic drugs [2]. AFLD was defined as FL associated with
ethanol intake ≥2 alcohol units / day in women and ≥ 3 al-
cohol units / day in men testing negative for HBsAg and
anti-HCV and not treated with steatogenic drugs [2].
Statistical analysis
Most continuous variables were not Gaussian-distributed
and all are reported as median and interquartile range.
Discrete variables are reported as the number and pro-
portion of subjects with the characteristic of interest.
Between-group comparisons of discrete variables were
performed using Pearson’s Chi-square test and those of
continuous variables using median regression with
heteroskedasticity-robust standard errors [25].
Binary logistic regression was used to evaluate the as-
sociation between FL and potential risk factors by means
of six pre-specified models [26, 27]. The outcome of all
the logistic regression models was FL (discrete; 0 = no; 1
= yes). Model 1 had ALE (0 = no; 1 = yes) as predictor;
Model 2 added sex (0 = female, 1 =male) and age (con-
tinuous, years/10) to Model 1; Model 3 added BMI (con-
tinuous, kg/m2/5) and ethanol intake (continuous,
alcohol units) to Model 2; Model 4 replaced BMI in
Model 3 with WC (continuous, cm/10); Model 5 added
MS (discrete, 0 = no; 1 = yes) and ethanol intake (con-
tinuous, alcohol units) as predictors to Model 2; Model
6 replaced MS in Model 5 with its single components,
i.e. large WC (discrete, 0 = no; 1 = yes), high triglycerides
(discrete, 0 = no; 1 = yes), low HDL (discrete, 0 = no;
1 = yes), high blood pressure (discrete, 0 = no; 1 = yes)
and high glucose (discrete, 0 = no; 1 = yes). Before fitting
the logistic regression models, we used univariable and
multivariable scatterplot smoothers to get an idea of the
functional form and shape of the continuous predictors
and found no evidence of deviation from linearity for any
predictor [28]. We also checked that the multivariable
logits of the continuous predictors were linear using mul-
tivariable fractional polynomials [29]. Because alcohol in-
take as quantified by the present study is strictly speaking
an ordinal and not a continuous variable, we tested
whether its multivariable relationship with FL was linear
by modeling it as both continuous and discrete in the
same model [30]. We found that the relationship was lin-
ear in all models (data not shown). We also tested whether
age and gender interacted in the models involving them
(Models 2 to 6) and found that they did not (data not
shown). Even if ethanol was not associated with FL, we
nonetheless evaluated its interaction with BMI and WC
because of its potential clinical significance [3]. We found
no evidence of interaction of ethanol with both BMI and
WC (data not shown). We evaluated the presence of col-
linearity among predictors in all models using the
Belsley-Kuh-Welsch condition number [31]. We com-
pared models using Akaike information criterion (AIC)
and the Bayesian information criterion (BIC) and add-
itionally calculated Nagelkerke pseudo-R2 and the area the
under the receiver-operating characteristic curve
(-ROC-AUC) [26]. We used Model 3 to calculate and plot
the sex-specific marginal probabilities of FL corresponding
to the 5th, 25th, 50th, 75th and 95th internal percentiles
of age and BMI at the median intake of ethanol [27, 32].
Multinomial logistic regression was used to evaluate
the association between FL type and potential predictors
by means of six pre-specified models [26, 27]. The out-
come of all the multinomial logistic regression models
was FL type (discrete; 0 = NAFLD; 1 = normal liver; 2 =
AFLD). The prediction models were the same described
above under binary logistic regression with the exception
that ethanol was not entered into any model. We set
NAFLD as the reference category in order to obtain esti-
mates of effect sizes for the normal liver vs. NAFLD and
the AFLD vs. AFLD comparisons. We performed the
same tests of model assumptions described above under
binary logistic regression. We compared models using
Akaike information criterion (AIC) and the Bayesian in-
formation criterion (BIC) and additionally calculated
Nagelkerke pseudo-R2. ROC-AUC were calculated for the
two binary logistic models underlying the multinomial lo-
gistic model. Statistical analysis was performed using Stata
15.1 (Stata Corporation, College Station, TX, USA).
Results
Flow of the citizens through the study
The flow of the citizens through the study is depicted in
Fig. 1. Four thousand and thirty-three (58%) of the 6920
citizens aged 30 to 60 years who resided in Bagnacavallo
as of January 2005 agreed to participate to the study and
3933 (98%) of them had all the data required for ana-
lysis. The citizens were consecutively studied during the
first three days of every week (except for holidays)
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between October 2005 and March 2009. The study
protocol required that all ALE+ and at least 50% of
ALE- citizens were recalled to undergo LUS.
Comparison of the subjects with and without liver
ultrasonography among the citizens with altered liver
enzymes
Three hundred ninety-three (10%) of the 3933 citizens with
complete data were ALE+. Sixteen (4.1%) of them had
HBV or HCV infection and will not be considered here. Of
the remaining 377 ALE+ citizens, 349 (93%) underwent
LUS. Additional file 1: Table S1 compares the 349 ALE+
citizens with LUS to the 28 ALE+ citizens without LUS. As
compared to ALE+ citizens without LUS, ALE+ citizens
with LUS had higher values of triglycerides, ALT and GGT
(p < 0.05). Besides not being of great interest in itself [33],
the lack of statistical significance should be taken with an
additional degree of caution here owing to the low number
of ALE+ subjects without LUS (n = 28).
Comparison of the subjects with and without liver
ultrasonography among the citizens with normal liver
enzymes
Among the 3540 (90%) ALE- citizens, 38 had HBV or
HCV infection (1.1%) and will not be considered here.
Of the remaining 3502 ALE- citizens, 1810 (52%) under-
went LUS. Additional file 2: Table S2 compares the 1810
ALE- citizens with LUS to the 1692 ALE- citizens
without LUS. As compared to ALE- citizens without
LUS, ALE- citizens with LUS were more likely to be
male and had higher values of age, weight, BMI, WC,
glucose, triglycerides, cholesterol, LDL-cholesterol, sys-
tolic blood pressure, ALT, GGT and bilirubin (p ≤ 0.05).
Besides not being of great interest in itself [33], the pres-
ence of statistical significance should be taken with an
additional degree of caution here owing to the high
number of ALE- subjects with (n = 1810) and without
LUS (n = 1692).
Comparison of the citizens with and without altered liver
enzymes among those with liver ultrasonography
Table 1 compares the ALE+ and ALE- citizens with
availability of LUS. ALE+ citizens were more frequently
male and slightly younger than ALE- citizens. ALE+ citi-
zens had greater values of BMI, WC, glucose, triglycer-
ides, total cholesterol, LDL-cholesterol, systolic blood
pressure and diastolic blood pressure and lower values
of HDL-cholesterol.
Prevalence and risk factors for fatty liver
The prevalence of FL was 0.74 (95%CI 0.70 to 0.79)
among ALE+ and 0.35 (0.33 to 0.37) among ALE- citi-
zens (p < 0.001). The severity of FL (light vs. moderate
vs. severe) was also higher among ALE+ than ALE- citi-
zens. All the components of the MS and the MS itself
were more prevalent among ALE+ than ALE- subjects.
Fig. 1 Flow of the subjects through the study. Abbreviations: ALE = altered liver enzymes; HBV = Hepatitis B virus; HCV = hepatitis C virus; LUS =
liver ultrasonography; FL = fatty liver
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Table 1 Comparison of citizens with and without altered liver enzymes
ALE- ALE+ p-value*
n = 1810 n = 349
Age (years) 49 (41–56) 47 (40–55) 0.03
Male sex 812 (44.9%) 267 (76.5%) < 0.001
Weight (kg) 72.0 (61.0–82.0) 84.0 (74.0–95.0) < 0.001
Height (m) 1.68 (1.60–1.74) 1.73 (1.67–1.79) < 0.001
BMI (kg/m2) 25.1 (22.6–28.1) 27.9 (25.4–30.9) < 0.001
BMI class (NIH) < 0.001
Underweight 19 (1.0%) 0 (0.0%)
Normal 871 (48.1%) 66 (18.9%)
Overweight 607 (33.5%) 170 (48.7%)
Obesity class 1 230 (12.7%) 81 (23.2%)
Obesity class 2 65 (3.6%) 28 (8.0%)
Obesity class 3 18 (1.0%) 4 (1.1%)
Fatty liver 637 (35.2%) 259 (74.2%) < 0.001
Fatty liver degree < 0.001
Light 428 (67.2%) 107 (41.3%)
Moderate 151 (23.7%) 102 (39.4%)
Severe 58 (9.1%) 50 (19.3%)
Fatty liver type < 0.001
None 1173 (64.8%) 90 (25.8%)
NAFLD 407 (22.5%) 160 (45.8%)
AFLD 230 (12.7%) 99 (28.4%)
Waist circumference (cm) 100.0 (93.0–107.0) 105.0 (100.0–113.0) < 0.001
Large waist circumference 1236 (68.3%) 259 (74.2%) 0.028
Glucose (mg/dl) 89 (83–96) 93 (87–102) < 0.001
High fasting glucose 307 (17.0%) 109 (31.2%) < 0.001
Triglycerides (mg/dl) 97 (68–139) 138 (98–206) < 0.001
High triglycerides 405 (22.4%) 159 (45.6%) < 0.001
Total cholesterol (mg/dl) 207 (184–234) 215 (192–240) 0.005
HDL cholesterol (mg/dl) 61 (51–73) 50 (44–61) < 0.001
Low HDL 219 (12.1%) 64 (18.3%) 0.002
LDL cholesterol (mg/dl) 126 (104–150) 138 (117–159) < 0.001
Systolic blood pressure (mm Hg) 125 (120–140) 130 (120–140) < 0.001
Diastolic blood pressure (mm Hg) 80 (80–90) 85 (80–90) < 0.001
High blood pressure 1053 (58.2%) 270 (77.4%) < 0.001
Metabolic syndrome 444 (24.5%) 171 (49.0%) < 0.001
Metabolic syndrome score < 0.001
0 216 (11.9%) 19 (5.4%)
1 595 (32.9%) 59 (16.9%)
2 555 (30.7%) 100 (28.7%)
3 294 (16.2%) 97 (27.8%)
4 117 (6.5%) 59 (16.9%)
5 33 (1.8%) 15 (4.3%)
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Lastly, alcohol intake was higher in ALE+ than in ALE-
subjects.
Table 2 reports the logistic regression models used to
investigate the association between FL and potential risk
factors.
Model 1 shows that the odds of FL was 5.3 (95%CI 4.1
to 6.9) times higher in ALE+ than in ALE- citizens. The
corresponding probabilities of FL estimated from the lo-
gistic regression model are 74% (95%CI 70 to 79%) for
ALE+ and 35% (95%CI 33 to 37%) for ALE- citizens.
Model 2 evaluates whether sex and age are associated with
FL independently from ALE. While both sex (OR= 2.1,
95%CI 1.7 to 2.5 for males) and age (OR= 1.8, 95%CI 1.6 to
2.0 per decade) show an independent effect on FL, the OR
of ALE changed only slightly (4%) compared to Model 1.
Model 3, obtained by adding BMI and alcohol intake
as predictors to Model 2, shows that BMI is associated
with FL (OR = 3.9, 95%CI 3.3 to 4.5 per 5 kg/m2) with
modest changes of the OR of sex (5%) and age (11%)
and with a moderate change of the OR of ALE (23%).
Table 1 Comparison of citizens with and without altered liver enzymes (Continued)
ALE- ALE+ p-value*
n = 1810 n = 349
ALT (U/l) 20 (15–26) 50 (44–63) < 0.001
AST (U/l) 20 (18–24) 33 (29–41) < 0.001
GGT (U/l) 17 (12–26) 42 (27–69) < 0.001
Total bilirubin (mg/dl) 0.60 (0.40–0.81) 0.62 (0.49–0.90) 0.003
Alcohol intake (alcohol units/day) 2 (0–4) 3 (1–5) < 0.001
Wine intake (alcohol units/day) 2 (0–2) 2 (1–3) < 0.001
Beer intake (alcohol units/day) 0 (0–1) 0 (0–1) 0.52
Liquor intake (alcohol units/day) 0 (0–0) 0 (0–1) < 0.001
Values are given as median (interquartile range) for continuous variables and number (proportion) for dichotomous variables
Abbreviations: ALE altered liver enzymes, BMI body mass index, NAFLD non-alcoholic fatty liver disease, AFLD alcoholic fatty liver disease, NIH National Institutes of
Health, HDL high-density lipoprotein, LDL low-density lipoprotein, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transferase
*Median regression for continuous variables and Pearson’s Chi-square test for binary categorical variables
Table 2 Logistic regression models used to investigate the association between fatty liver and potential risk factors
M1 M2 M3 M4 M5 M6
ALE 5.3** [4.1 to 6.9] 5.1** [3.9 to 6.7] 3.9** [2.9 to 5.2] 4.0** [3.0 to 5.4] 4.2** [3.2 to 5.6] 3.7** [2.8 to 5.0]
Male – 2.1** [1.7 to 2.5] 2.0** [1.6 to 2.5] 2.1** [1.7 to 2.6] 2.0** [1.6 to 2.4] 2.4** [1.9 to 3.0]
Age (years) / 10 – 1.8** [1.6 to 2.0] 1.6** [1.4 to 1.8] 1.5** [1.4 to 1.7] 1.5** [1.4 to 1.7] 1.4** [1.3 to 1.6]
BMI (kg/m2) / 5 – – 3.9** [3.3 to 4.5] – – –
Alcohol intake (units) – – 1.0 [0.9 to 1.0] 1.0 [1.0 to 1.1] – –
Waist circumference (cm) / 10 – – – 2.5** [2.3 to 2.8] – –
Metabolic syndrome – – – – 5.1** [4.1 to 6.3] –
Large waist circumference – – – – – 2.9** [2.3 to 3.8]
High triglycerides – – – – – 3.1** [2.4 to 3.9]
Low HDL – – – – – 1.6* [1.2 to 2.2]
High blood pressure – – – – – 1.9** [1.5 to 2.3]
High glucose – – – – – 2.0** [1.5 to 2.6]
n 2159 2159 2159 2159 2159 2159
AIC 2750 2595 2131 2244 2376 2266
BIC 2762 2618 2165 2278 2405 2317
ROC-AUC 0.61 0.72 0.83 0.81 0.79 0.81
Pseudo-R2 (Nagelkerke) 0.11 0.20 0.42 0.37 0.31 0.36
Values are odds ratios and 95% confidence intervals (logistic regression)
Abbreviations: M# model number, ALE altered liver enzymes, BMI body mass index, HDL high-density lipoprotein, AIC Akaike information criterion, BIC Bayesian
information criterion, ROC-AUC area under the ROC curve, pseudo-R2 pseudo-squared R
*p < 0.01; **p < 0.001
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Importantly, this model shows that ethanol intake is not
associated with FL (OR = 1.0, 95%CI 1.0 to 1.1 per alco-
hol unit). All the employed metrics of model fit identi-
fied Model 3 as the best of all models (lowest AIC,
lowest BIC, highest ROC-AUC and highest pseudo-R2).
Model 4, obtained by replacing BMI in Model 3 with
WC, shows that WC is associated with FL (OR = 2.5,
95%CI 2.3 to 2.8) independently of ALE, sex and alcohol
intake. The effect sizes of ALE, sex and age are similar to
those of Model 3 using BMI as predictor and ethanol in-
take is again not associated with FL. (We did not evaluate
BMI and WC together in Model 4 because of the evidence
of collinearity as determined by a Belsley-Kuh-Welsch
condition number of 31).
Model 5 evaluates the association of MS with FL tak-
ing into account ALE, sex and age. Having MS is associ-
ated with an odds of FL equal to 5.1 (95%CI 4.1 to 6.3).
(Neither BMI nor WC were entered into this model be-
cause WC is already included in the definition of MS
and BMI and WC were collinear as explained above.)
Model 6 evaluates the independent contribution of each
component of the MS (large WC, high triglycerides, low
HDL, high blood pressure and high glucose) to FL. Not
only was each component of the MS associated with FL,
but all the measures of model fit were better for Model 6
than for Model 5 (lower AIC, lower BIC, higher
ROC-AUC and higher pseudo-R2), showing that there is
some advantage in considering the single components of
the MS instead of the MS as its association with FL is
concerned.
Figure 2 plots the prevalence of FL in men and women
with and without ALE as estimated by Model 3 with
ethanol intake set at the median value [32]. In both
sexes, the prevalence of FL increases with age and BMI.
Prevalence of and risk factors for NAFLD and AFLD
The prevalence of NAFLD and AFLD in ALE+ and ALE-
subjects was 0.46 (0.41 to 0.51) vs. 0.22 (95%CI 0.21 to
0.24) and 0.28 (0.24 to 0.33) vs. 0.13 (CI 0.11 to 0.14).
Table 3 reports the multinomial logistic regression
models used to investigate the association between FL
type and potential risk factors.
Not unexpectedly, all potential risk factors were asso-
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Fig. 2 Prevalence of fatty liver in men and women with and without altered liver enzymes as estimated by Model 3 of Table 2. Values are
proportions and pointwise 95% confidence intervals. Abbreviations: ALE = altered liver enzymes; FL = fatty liver; BMI = body mass index. The values
of age correspond to the 5th (34 yr), 25th (41 yr), 50th (49 yr), 75th (56 yr) and 95th (61 yr) internal percentiles. The values of BMI correspond to
the 5th (19.7 kg/m2), 25th (23.0 kg/m2), 50th (25.5 kg/m2), 75th (28.9 kg/m2) and 95th (35.1 kg/m2) internal percentiles and alcohol intake is set to
the median value
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odds ratios were in fact < 1 for all predictors (Models 1–
6). More interestingly, the same predictors were unable
to discriminate AFLD from NAFLD as made clear by
the unsatisfactory ROC-curves of the binary ALFD vs.
NAFLD model.
In detail, ALE (Models 1–6), BMI (Model 3), WC
(Model 4) and MS (Model 5) were not associated with the
odds of having AFLD vs. NAFLD. Although male gender
and lower age were associated with a greater odds of AFLD
vs. NAFLD in all models (Models 1–6), their 95%CI are
wide. It is of some interest that high WC and low HDL
made AFLD less likely than NAFLD and that high triglyc-
erides made AFLD more likely than NAFLD (Model 6) but
the 95%CI of these estimates are again wide.
Discussion
Although much more epidemiological data are presently
available on FL as compared to when the Dionysos Study
Table 3 Multinomial logistic regression models used to investigate the association between fatty liver type and potential risk factors
M1 M2 M3 M4 M5 M6
Normal liver vs. NAFLD
Altered liver enzymes 0.20*** [0.15,0.26] 0.19*** [0.14,0.25] 0.25*** [0.18,0.34] 0.24*** [0.17,0.33] 0.23*** [0.17,0.31] 0.26*** [0.19,0.35]
Male sex – 0.61*** [0.49,0.75] 0.65*** [0.51,0.82] 0.58*** [0.46,0.73] 0.64*** [0.51,0.81] 0.49*** [0.37,0.64]
Age (years) / 10 – 0.53*** [0.46,0.60] 0.60*** [0.52,0.69] 0.61*** [0.53,0.70] 0.61*** [0.53,0.70] 0.65*** [0.56,0.75]
BMI (kg/m2) / 5 – – 0.26*** [0.22,0.30] – – –
WC (cm) / 10 – – – 0.39*** [0.34,0.43] – –
Metabolic syndrome – – – – 0.20*** [0.16,0.26] –
High waist circumference – – – – – 0.29*** [0.21,0.39]
High triglycerides – – – – – 0.38*** [0.29,0.50]
Low HDL – – – – – 0.54*** [0.39,0.76]
High blood pressure – – – – – 0.56*** [0.43,0.72]
High fasting glucose – – – – – 0.52*** [0.39,0.69]
n 1830 1830 1830 1830 1830 1830
ROC-AUC 0.61 0.72 0.83 0.82 0.78 0.81
AFLD vs. NAFLD
Altered liver enzymes 1.09 [0.81,1.48] 0.89 [0.65,1.21] 0.87 [0.64,1.20] 0.91 [0.66,1.24] 0.87 [0.63,1.19] 0.87 [0.63,1.20]
Male sex – 1.95*** [1.44,2.63] 1.96*** [1.44,2.65] 1.89*** [1.39,2.56] 1.95*** [1.44,2.64] 1.52* [1.09,2.13]
Age (years) / 10 – 0.82* [0.70,0.97] 0.83* [0.70,0.97] 0.84* [0.71,0.99] 0.82* [0.69,0.97] 0.80* [0.67,0.96]
BMI (kg/m2) / 5 – – 1.01 [0.87,1.17] – – –
WC (cm) / 10 – – – 0.92 [0.81,1.03] – –
Metabolic syndrome – – – – 1.05 [0.79,1.39] –
High waist circumference – – – – – 0.68* [0.47,0.97]
High triglycerides – – – – – 1.58** [1.17,2.13]
Low HDL – – – – – 0.64* [0.44,0.93]
High blood pressure – – – – – 1.10 [0.78,1.56]
High fasting glucose – – – – – 1.12 [0.82,1.53]
n 896 896 896 896 896 896
ROC-AUC 0.51 0.60 0.60 0.61 0.61 0.63
Whole model
N 2159 2159 2159 2159 2159 2159
AIC 3932 3754 3290 3402 3537 3419
BIC 3955 3800 3347 3459 3594 3521
Pseudo-R2 (Nagelkerke) 0.10 0.19 0.38 0.34 0.28 0.34
Values are odds ratios and 95% confidence intervals (multinomial logistic regression). ROC-AUC were calculated for the two binary logistic models underlying the
multinomial logistic model
Abbreviations: M# model number, NAFLD non-alcoholic fatty liver disease, BMI body mass index, WC waist circumference, HDL high-density lipoprotein, AFLD
alcoholic fatty liver disease, AIC Akaike information criterion, BIC Bayesian information criterion, ROC-AUC area under the ROC curve, pseudo-R2 pseudo-squared R
*p < 0.05; **p < 0.01; ***p < 0.001
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was performed [3, 8], there are still few studies performed
in representative samples of the general population [10].
FL has a different course in the general population than in
primary, secondary and tertiary care centers, where most
of the presently available studies on FL were performed
[34]. This is in line with the so-called “ecology of medical
care” model, according to which only a minority of citi-
zens with a given illness will actually search for and get
medical care [14]. Thus, the real burden attributable to FL
cannot be estimated without epidemiological data ob-
tained from the general population [15].
The strengths of the present study are that it was per-
formed in a representative sample of the general popula-
tion, that it enrolled a high number of subjects, and that
it built a serum bank that we plan to use in future stud-
ies. The most important limitation of the study is the
suboptimal response rate (58%). Although this response
rate is the same of the Dionysos Nutrition & Liver Study
[8] and is higher than that reported by most studies [35],
it is possible that the citizens who refused to participate
to the Bagnacavallo Study differed systematically from
those who accepted to participate with an ensuing selec-
tion bias. Another limitation of the present study is the
use of LUS to diagnose FL. Although LUS is virtually the
only feasible option to diagnose FL in population stud-
ies, it is known to offer an accurate assessment of FL
only starting from an intrahepatic triglyceride content of
10% [5, 36]. Thus, lesser degrees of FL may have gone
undetected in the present study and our estimates of FL
prevalence may be conservative.
In the present study, 74% of ALE+ citizens had FL
compared to 35% of ALE- citizens. In the Dionysos Nu-
trition & Liver Study, performed in the same region of
Northern Italy during 2002/3, 44% of citizens with sus-
pected liver disease had FL as compared to 35% of those
without suspected liver disease [8]. The estimates made
by the Bagnacavallo Study and by the Dionysos Nutri-
tion & Liver Study are unfortunately not comparable be-
cause of the different operational definitions of ALE and
suspected liver disease. The criteria for suspected liver
disease adopted by the Dionysos Nutrition & Liver Study
did in fact include an altered GGT (> 35 U/l), did not
consider AST, and did consider an ALT > 30 U/l as al-
tered [8]. The Bagnacavallo Study confirms nonetheless,
as firstly shown by the Dionysos Nutrition & Liver Study
in a general population [8], that FL is quite common
(35%) among subjects with normal liver enzymes.
The analysis of the potential risk factors for FL yielded
two very interesting findings. The first finding is that
ethanol intake was not an independent predictor of FL
in the general population. The Dionysos Nutrition &
Liver Study reported the same finding even if a direct
comparison of the Dionysos Nutrition & Liver Study
and the Bagnacavallo Study is not possible because of
the different instruments used to measure alcohol intake
[9]. The second finding is that all the components of the
MS were associated to FL independently of ALE, gender,
age and alcohol intake. The dichotomization implicit in
the concept of MS has been criticized by research meth-
odologists on the basis of both clinical and statistical
grounds [5, 37]. The findings of the present study offer a
further empirical argument for preferring the use of the
single components of the MS instead of the whole MS
for the study of the association of FL as a whole with
cardiometabolic risk factors.
Prevalence of and risks factors for non-alcoholic fatty
liver disease and alcoholic fatty liver disease
Although the present study focused on FL as a whole
considering ethanol intake as a potential predictor, we
performed an analysis of the prevalence of and the risk
factors for NAFLD to allow a comparison with the avail-
able studies [10].
In the present study, the prevalence of NAFLD was
46% among ALE+ and 22% among ALE- citizens. The
corresponding figures for citizens with and without sus-
pected liver disease in the Dionysos Nutrition & Liver
Study were 25 and 20% [8]. The Bagnacavallo Study and
Dionysos Nutrition & Liver Study estimates are unfortu-
nately not comparable not only because of the different
operational definitions of ALE and suspected liver dis-
ease as discussed above, but also because the Dionysos
Nutrition & Liver Study employed a different cut-point
of alcohol intake to diagnose NAFLD in men (≤ 20 g/
day) and used a different instrument (7-day prospective
diary) to measure ethanol intake [8]. We have, indeed,
previously shown that small errors in the estimation of
ethanol intake may lead to a substantial difference in the
estimated prevalence of NAFLD vs. AFLD [5, 8].
The analysis of the potential risk factors for NAFLD
yielded a very interesting finding. All potential risk fac-
tors were associated with a lower odds of normal liver
vs. NAFLD in all models, which were able to satisfactor-
ily discriminate NAFLD from normal liver. However, the
same models were not able to discriminate AFLD from
NAFLD. There are several, not mutually exclusive, ex-
planations for this finding. First, the dichotomization of
ethanol intake, central to the separation of NAFLD from
AFLD [38], could have introduced substantial bias into
the inference [37]. Second, we have not cross-validated
the recall method used to assess ethanol intake in the
present study against an accepted reference method, e.g.
the 7-day prospective diary used the Dionysos Nutrition
& Liver Study [8]. Thus, we ignore the measurement
error of the method used to assess ethanol intake [39].
This is unfortunately the rule in the literature on FL and is
especially troublesome because the separation of NAFLD
from AFLD is based entirely on the dichotomization of
Foschi et al. BMC Gastroenterology          (2018) 18:177 Page 9 of 11
alcohol intake [38]. Third, it is possible that the separation
between NAFLD and AFLD is not relevant at the popula-
tion level because most of the risk factors for FL as whole
are not associated with its separation into NAFLD and
AFLD. However, without accurate measurements of etha-
nol intake, this hypothesis remains highly speculative. In
view of the fact that ethanol is a well-known hepatotoxic
agent, our data should not be taken as evidence that etha-
nol intake is not an individual risk factor for fatty liver but
simply that with conventional instruments used to detect
fatty liver and measure ethanol intake, this relationship was
not evident at the population level in Bagnacavallo in
2005/2009.
Conclusions
In conclusion, FL was highly prevalent in a Northern Italy
town in 2005/9 and was more common among ALE indi-
viduals. It had no association with alcohol intake but was
strongly associated with anthropometry and all the MS
components. NAFLD was more common than AFLD but,
while anthropometry and all the MS components were
able to discriminate normal liver from NAFLD, they did
not discriminate AFLD from NAFLD. The cross-sectional
data presented in this paper will inform the ongoing and
future analyses of the Bagnacavallo cohort, which we hope
will offer new and relevant information on the burden of
FL in the general population.
Additional files
Additional file 1: Table S1. Comparison of the citizens with and
without liver ultrasonography among those with altered liver enzymes. In
this table we compared the 349 citizens with altered liver enzymes (ALE
+) and with liver ultrasonography (LUS) to the 28 ALE+ citizens without
LUS. (DOCX 18 kb)
Additional file 2: Table S2. Comparison of the citizens with and
without liver ultrasonography among those with normal liver enzymes. In
this table we compared the 1810 citizens without altered liver enzymes
(ALE-) and with liver ultrasonography (LUS) to the 1692 ALE- citizens
without LUS. (DOCX 18 kb)
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